This minireview on skeletal biology describes the actions of prostaglandins and cytokines involved in the local regulation of bone metabolism, it documents the role of lipids in bone biology, and it presents relationships between fatty acids and other factors that impact skeletal metabolism. The data presented herein show consistent and reproducible beneficial effects of omega-3 (n-3) fatty acids on bone metabolism and bone/joint diseases. Polyunsaturated fatty acids modulate eicosanoid biosynthesis in numerous tissues and cell types, alter signal transduction, and influence gene expression. These effects have not been explored in the skeletal system. Future research on n-3 fatty acids in bone biology should focus on the following two aspects. First, the further elucidation of how n-3 fatty acids alter biochemical and molecular processes involved in bone modeling and bone cell differentiation, and second, the evaluation of the potential pharmaceutical applications of these nutraceutical fatty acids in maintaining bone mineral status and controlling inflammatory bone/joint diseases.
U.S. Department of Health and Human Services National Center for Health Statistics. DHHS Publication no. (PHS)961232, 1995.
2.
SimopoulosAP. Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukot Essent Fatty Acids60: 421429, 1999.
3.
BaronR. Anatomy and ultrastructure of bone. In: FavusMJ, Ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2nd edition). New York: Raven Press, pp 39, 1993.
4.
BaylinkDJ, FinkelmanRD, MohanS. Growth factors to stimulate bone formation. J Bone Miner Res8: S565S572, 1993.
5.
MundyGR. Cytokines and growth factors in the regulation of bone remodeling. J Bone Miner Res8: S505S510, 1993.
6.
RaiszLG. Bone cell biology: New approaches and unanswered questions. J Bone Miner Res8: S457S465, 1993.
7.
CanalisE. Regulation of bone remodeling. In: FavusMJ Ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2nd edition). New York: Raven Press, pp 3337, 1993.
WatrousDA, AndrewsBS. The metabolism and immunology of bone. Semin Arthritis Rheum19: 4565, 1989.
10.
NilssonA, OhlssonC, IsakssonOG, LindahlA, IsgaardJ. Hormonal regulation of longitudinal bone growth. Eur J Clin Nutr48: S150S158, 1994.
11.
ChowJ, TobiasJH, ColstonKW, ChambersTJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest89: 7478, 1992.
12.
RaiszLG. Recent advances in bone cell biology: Interactions of vitamin D with other local and systemic factors. Bone Miner9: 191197, 1990.
13.
KreamBE, PetersenDN, RaiszLG. Parathyroid hormone blocks the stimulatory effect of insulin-like growth factor-I on collagen synthesis in cultured 21-day fetal rat calvariae. Bone11: 411415, 1990.
14.
KlaushoferK, HoffmannO, GleispachH, LeisHJ, CzerwenkaE, KollerK, PeterlikM. Bone-resorbing activity of thyroid hormones is related to prostaglandin production in cultured neonatal mouse calvaria. J Bone Miner Res4: 305312, 1989.
15.
LukertBP, RaiszLG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med112: 352364, 1990.
16.
HofbauerLC, GoriF, RiggsBL, LaceyDL, DunstanCR, SpelsbergTC, KhoslaS. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology140: 43824389, 1999.
17.
LinHY, HarrisTL, FlanneryMS, AruffoA, KajiEH, GornA, KolakowskiLFJr., LodishHF, GoldringSR. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science254: 10221024, 1991.
18.
LinkhartTA, MohanS, BaylinkDJ. Growth factors for bone growth and repair: IGF, TGF beta and BMP. Bone19: 1S12S, 1996.
19.
MarusicA, RaiszLG. Cortisol modulates the actions of interleukin-1 alpha on bone formation, resorption, and prostaglandin production in cultured mouse parietal bones. Endocrinology129: 26992706, 1991.
20.
KajiY, IkedaK, IkedaT, KawakamiK, SasakiK, ShindoM, HatakeK, HaradaM, MotoyoshiK, MoriS, NorimatsuH, TakaharaJ. IL-4, but not vitamin D3, induces monoblastic cell line UG3 to differentiate into multinucleated giant cells on osteoclast lineage. J Cell Physiol182: 214221, 2000.
21.
IshimiY, MiyauraC, JinCH, AkatsuT, AbeE, NakamuraY, YamaguchiA, YoshikiS, MatsudaT, HiranoT. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol145: 32973303, 1990.
22.
GreyA, MitnickMA, MasiukiewiczU, SunBH, RudikoffS, JilkaRL, ManolagasSC, InsognaK. A role for interleukin-6 in parathyroid hormone-induced bone resorption in in vivo. Endocrinology140: 46834690, 1999.
23.
MorinagaY, FujitaN, OhishiK, ZhangY, TsuruoT. Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors. J Cell Physiol175: 247254, 1998.
24.
HillPA, TumberA, PapaioannouS, MeikleMC. The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology139: 15641572, 1998.
25.
IdrissHT, NaismithJH. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). Microsc Res Technol50: 184195, 2000.
26.
AzumaY, KajiK, KatogiR, TakeshitaS, KudoA. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem275: 48584864, 2000.
27.
LorenzoJA, QuintonJ, SousaS, RaiszLG. Effects of DNA and prostaglandin synthesis inhibitors on the stimulation of bone resorption by epidermal growth factor in fetal rat long-bone cultures. J Clin Invest77: 18971902, 1986.
28.
SimmonsHA, RaiszLG. Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones. J Bone Miner Res6: 13011305, 1991.
29.
ManabeN, OdaH, NakamuraK, KugaY, UchidaS, KawaguchiH. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology38: 714720, 1999.
30.
CanalisE, McCarthyTL, CentrellaM. Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol140: 530537, 1989.
31.
BesseA, TrimoreauF, FaucherJL, PraloranV, DenizotY. Prostaglandin E2 regulates macrophage colony stimulating factor secretion by human bone marrow stromal cells. Biochim Biophys Acta1450: 444451, 1999.
32.
McCarthyTL, CentrellaM, CanalisE. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology124: 301309, 1989.
33.
CanalisE, CentrellaM, McCarthyTL. Regulation of insulin-like growth factor-II production in bone cultures. Endocrinology129: 24572462, 1991.
34.
DunstanCR, BoyceR, BoyceBF, GarrettIR, IzbickaE, BurgessWH, MundyGR. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res14: 953959, 1999.
35.
CentrellaM, McCarthyTL, CanalisE. Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem262: 28692874, 1987.
36.
FullerK, LeanJM, BayleyKE, ChambersTJ. A role for TGF β1 in osteoclast differentiation and survival. J Cell Sci113: 24452453, 2000.
37.
HongMH, WilliamsH, JinCH, PikeJW. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J Bone Miner Res15: 911918, 2000.
38.
DunstanCR. Osteoprotegerin and osteoprotegerin ligand mediate the local regulation of bone resorption. Endocrinologist10: 1826, 2000.
39.
LeeSK, LorenzoJA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology140: 35523561, 1999.
40.
KanzawaM, SugimotoT, KanataniM, ChiharaK. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol142: 661664, 2000.
41.
KoideM, MuraseY, YamatoK, NoguchiT, OkahashiN, NishiharaT. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun259: 97102, 1999.
42.
SudaT, UdagawaN, NakamuraI, MiyauraC, TakahashiN. Modulation of osteoclast differentiation by local factors. Bone17: 87S91S, 1995.
43.
HorwoodNJ, ElliottJ, MartinTJ, GillespieMT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology139: 47434746, 1998.
44.
TakayanagiH, IizukaH, JujiT, NakagawaT, YamamotoA, MiyazakiT, KoshiharaY, OdaH, NakamuraK, TanakaS. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum43: 259269, 2000.
45.
GravalleseEM, ManningC, TsayA, NaitoA, PanC, AmentoE, GoldringSR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum43: 250258, 2000.
46.
BrandstromH, JonssonKB, OhlssonC, VidalO, LjunghallS, LjunggrenO. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem Biophys Res Commun247: 338341, 1998.
47.
MurakamiT, YamamotoM, OnoK, NishikawaM, NagataN, MotoyoshiK, AkatsuT. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun252: 747752, 1998.
48.
NagaiM, KyakumotoS, SatoN. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun269: 532536, 2000.
49.
BautistaCM, BaylinkDJ, MohanS. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: A potential candidate for fixing IGF-II in human bone. Biochem Biophys Res Commun176: 756763, 1991.
50.
MohanS, BaylinkDJ. Bone growth factors. Clin Orthop263: 3048, 1991.
51.
McCarthyTL, CentrellaM, RaiszLG, CanalisE. Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. Endocrinology128: 28952900, 1991.
52.
KimJG, ShinCS, ChoiYM, MoonSY, KimSY, LeeJY. The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60. Clin Endocrinol51: 301307, 1999.
53.
GarneroP, Sornay-RenduE, DelmasPD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet355: 898899, 2000.
54.
CaloL, CastrignanoR, DavisPA, CarraroG, PagninE, GianniniS, SempliciniA, D'angeloA. Role of insulin-like growth factor-I in primary osteoporosis: A correlative study. J Endocrinol Invest23: 223227, 2000.
55.
HedstromM. Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. Acta Physiol Scand167: 347350, 1999.
56.
ParkhouseWS, CouplandDC, LiCM, VanderhoekKJ. IGF-1 bioavailability is increased by resistance training in older women with low bone mineral density. Mech Aging Dev113: 7583, 2000.
57.
KleinDC, RaiszLG. Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology86: 14361440, 1970.
58.
NorrdinRW, JeeWS, HighWB. The role of prostaglandins in bone in vivo. Prostaglandins Leukot Essent Fatty Acids41: 139149, 1990.
59.
MarksSCJr., MillerSC. Prostaglandins and the skeleton: The legacy and challenges of two decades of research. Endocr J1: 337344, 1993.
60.
RaiszLG, FallPM. Biphasic effects of prostaglandin E2 on bone formation in cultured fetal rat calvariae: Interaction with cortisol. Endocrinology126: 16541659, 1990.
61.
HakedaY, NakataniY, KuriharaN, IkedaE, MaedaN, KumegawaM. Prostaglandin E2 stimulates collagen and non-collagen protein synthesis and prolyl hydroxylase activity in osteoblastic clone MC3T3-E1 cells. Biochem Biophys Res Commun126: 340345, 1985.
62.
IgarashiK, HirafujiM, AdachiH, ShinodaH, MitaniH. Role of endogenous PGE2 in osteoblastic functions of a clonal osteoblast-like cell, MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids50: 169172, 1994.
63.
JeeWS, MoriS, LiXJ, ChanS. Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone11: 253266, 1990.
64.
MoriS, JeeWS, LiXJ, ChanS, KimmelDB. Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of ovariectomized rats. Bone11: 103113, 1990.
65.
YaoW, JeeWSS, ZhouH, LuJ, CuiL, SetterbergR, LiangT, MaY. Anabolic effect of prostaglandin E2 on cortical bone of aged male rats comes mainly from modeling-dependent bone gain. Bone25: 697702, 1999.
66.
TakahashiM, HoshinoH, IshiharaC, KushidaK, InoueT. The effect of prostaglandin E, on human bone metabolism: Evaluation by biochemical markers for bone turnover. Endocr Res26: 119128, 2000.
67.
CollinsDA, ChambersTJ. Prostaglandin E2 promotes osteoclast formation in murine hematopoietic cultures through an action on hematopoietic cells. J Bone Miner Res7: 555561, 1992.
68.
TashjianAHJr., VoelkelEF, LazzaroM, GoadD, BosmaT, LevineL. Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology120: 20292036, 1987.
69.
TashjianAHJr., VoelkelEF, LazzaroM, SingerFR, RobertsAB, DerynckR, WinklerME, LevineL. Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc Natl Acad Sci USA82: 45354538, 1985.
70.
TashjianAHJr., HohmannEL, AntoniadesHN, LevineL. Platelet-derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism. Endocrinology111: 118124, 1982.
71.
HurleyMM, LeeSK, RaiszLG, BerneckerP, LorenzoJ. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures. Bone22: 309316, 1998.
72.
TakiguchiT, KobayashiM, NagashimaC, YamaguchiA, NishiharaT, HasegawaK. Effect of prostaglandin E2 on recombinant human bone morphogenetic protein-2-stimulated osteoblastic differentiation in human periodontal ligament cells. J Periodontal Res34: 431436, 1999.
73.
WatkinsBA, ShenCL, AllenKG, SeifertMF. Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE2 biosynthesis, tissue IGF-I levels, and bone morphometry in chicks. J Bone Miner Res11: 13211332, 1996.
74.
WatkinsBA, ShenCL, McMurtryJP, XuH, BainSD, AllenKG, SeifertMF. Dietary lipids modulate bone prostaglandin E2 production, insulin-like growth factor-I concentration and formation rate in chicks. J Nutr127: 10841091, 1997.
75.
GruberR, NotheggerG, HoGM, WillheimM, PeterlikM. Differential stimulation by PGE2 and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun270: 10801085, 2000.
76.
TakaokaY, NiwaS, NagaiH. Interleukin-1 beta induces interleukin-6 production through the production of prostaglandin E2 in human osteoblasts, MG-63 cells. J Biochem126: 553558, 1999.
77.
OkadaY, LorenzoJA, FreemanAM, TomitaM, MorhamSG, RaiszLG, PilbeamCC. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest105: 823832, 2000.
78.
YasudaH, ShimaN, NakagawaN, YamaguchiK, KinosakiM, MochizukiS, TomoyasuA, YanoK, GotoM, MurakamiA, TsudaE, MorinagaT, HigashioK, UdagawaN, TakahashiN, SudaT. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA95: 35973602, 1998.
79.
KanematsuM, SatoT, TakaiH, WatanabeK, IkedaK, YamadaY. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: Implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res15: 13211329, 2000.
80.
ManolagasSC, JilkaRL. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N Engl J Med332: 305311, 1995.
81.
KimbleRB, SrivastavaS, RossFP, MatayoshiA, PacificiR. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem271: 2889028897, 1996.
82.
KawaguchiH, PilbeamCC, VargasSJ, MorseEE, LorenzoJA, RaiszLG. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest96: 539548, 1995.
83.
WatabeA, SugimotoY, HondaA, IrieA, NambaT, NegishiM, ItoS, NarumiyaS, IchikawaA. Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J Biol Chem268: 2017520178, 1993.
84.
KatsuyamaM, NishigakiN, SugimotoY, MorimotoK, NegishiM, NarumiyaS, IchikawaA. The mouse prostaglandin E receptor EP2 subtype: Cloning, expression, and northern blot analysis. FEBS Lett372: 151156, 1995.
85.
SugimotoY, NambaT, HondaA, HayashiY, NegishiM, IchikawaA, NarumiyaS. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem267: 64636466, 1992.
86.
IchikawaA, SugimotoY, NegishiM. Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Mediat Cell Signal14: 8387, 1996.
87.
IrieA, SugimotoY, NambaT, HarazonoA, HondaA, WatabeA, NegishiM, NarumiyaS, IchikawaA. Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem217: 313318, 1993.
88.
FujiedaM, KiriuM, MizuochiS, HagiyaK, KanekiH, IdeH. Formation of mineralized bone nodules by rat calvarial osteoblasts decreases with donor age due to a reduction in signaling through EP1 subtype of prostaglandin E2 receptor. J Cell Biochem75: 215225, 1999.
89.
MiyauraC, InadaM, SuzawaT, SugimotoY, UshikubiF, IchikawaA, NarumiyaS, SudaT. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem275: 1981919823, 2000.
90.
SakumaY, TanakaK, SudaM, YasodaA, NatsuiK, TanakaI, UshikubiF, NarumiyaS, SegiE, SugimotoY, IchikawaA, NakaoK. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res15: 218227, 2000.
91.
LiXD, OkadaY, PilbeamCC, LorenzoJA, KennedyCRJ, BreyerRM, RaiszLG. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology141: 20542061, 2000.
92.
SuzawaT, MiyauraC, InadaM, MaruyamaT, SugimotoY, UshikubiF, IchikawaA, NarumiyaS, SudaT. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: An analysis using specific agonists for the respective EPs. Endocrinology141: 15541559, 2000.
93.
RenW, DziakR. Effects of leukotrienes on osteoblastic cell proliferation. Calcif Tissue Int49: 197201, 1991.
MeghjiS, SandyJR, ScuttAM, HarveyW, HarrisM. Stimulation of bone resorption by lipoxygenase metabolites of arachidonic acid. Prostaglandins36: 139149, 1988.
96.
GarciaC, BoyceBF, GillesJ, DallasM, QiaoM, MundyGR, BonewaldLF. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res11: 16191627, 1996.
97.
Franchi-MillerC, SaffarJL. The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. Bone17: 185191, 1995.
98.
TraianedesK, DallasMR, GarrettIR, MundyGR, BonewaldLF. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology139: 31783184, 1998.
99.
WuthierRE. Involvement of cellular metabolism of calcium and phosphate in calcification of avian growth plate cartilage. J Nutr123: 301309, 1993.
100.
KrugerMC, CoetzerH, de WinterR, GerickeG, van PapendorpDH. Calcium, gammalinolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging10: 385394, 1998.
101.
GunnesM, LehmannEH. Dietary calcium, saturated fat, fiber and vitamin C as predictors of forearm cortical and trabecular bone mineral density in healthy children and adolescents. Acta Paediatr84: 388392, 1995.
102.
LiY, SeifertMF, NeyDM, GrahnM, GrantAL, AllenKG, WatkinsBA. Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n = 6) or (n-3) fatty acids. J Bone Miner Res14: 11531162, 1999.
103.
SakaguchiK, MoritaI, MurotaS. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids50: 8184, 1994.
104.
WatkinsBA, LiY, AllenKGD, HoffmannWE, SeifertMF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr130: 22742284, 2000.
105.
XuH, WatkinsBA, AdkissonHD. Dietary lipids modify the fatty acid composition of cartilage, isolated chondrocytes and matrix vesicles. Lipids29: 619625, 1994.
106.
WatkinsBA, XuH, TurekJJ. Linoleate impairs collagen synthesis in primary cultures of avian chondrocytes. Proc Soc Exp Biol Med212: 153159, 1996.
107.
WatkinsBA, LippmanHE, Le BouteillerL, LiY, SeifertMF. Bioactive fatty acids: Role in bone biology and bone cell function. Prog Lipid Res40: 125148, 2001.
108.
XuH, WatkinsBA, SeifertMF. Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Calcif Tissue Int57: 293300, 1995.
109.
AdkissonHD, RisenerFSJr., ZarrinkarPP, WallaMD, ChristieWW, WuthierRE. Unique fatty acid composition of normal cartilage: Discovery of high levels of n-9 eicosatrienoic acid and low levels of n-6 polyunsaturated fatty acids. FASEB J5: 344353, 1991.
110.
SeifertMF, WatkinsBA. Role of dietary lipid and antioxidants in bone metabolism. Nutr Res17: 12091228, 1997.
111.
WatkinsBA, SeifertMF, AllenKG. Importance of dietary fat in modulating PGE2 responses and influence of vitamin E on bone morphometry. World Rev Nutr Diet82: 250259, 1997.
112.
EvansDB, ThavarajahM, KanisJA. Involvement of prostaglandin E2 in the inhibition of osteocalcin synthesis by human osteoblast-like cells in response to cytokines and systemic hormones. Biochem Biophys Res Commun167: 194202, 1990.
113.
EvansDB, BunningRA, RussellRG. The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun166: 208216, 1990.
114.
IgarashiK, HirafujiM, AdachiH, ShinodaH, MitaniH. Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids56: 121125, 1997.
115.
KajiiT, SuzukiK, YoshikawaM, ImaiT, MatsumotoA, NakamuraS. Long-term effects of prostaglandin E2 on the mineralization of a clonal osteoblastic cell line (MC3T3-El). Arch Oral Biol44: 233241, 1999.
116.
AlamSQ, KokkinosPP, AlamBS. Fatty acid composition and arachidonic acid concentrations in alveolar bone of rats fed diets with different lipids. Calcif Tissue Int53: 330332, 1993.
117.
AtkinsonTG, BarkerHJ, Meckling-GillKA. Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats. Lipids32: 293302, 1997.
118.
KokkinosPP, ShayeR, AlamBS, AlamSQ. Dietary lipids, prostaglandin E2 levels, and tooth movement in alveolar bone of rats. Calcif Tissue Int53: 333337, 1993.
119.
VenkatramanJT, ChuWC. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr18: 602613, 1999.
120.
LoCJ, ChiuKC, FuMJ, LoR, HeltonS. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res82: 216221, 1999.
121.
HallworthRB. Prevention and treatment of postmenopausal osteoporosis. Pharm World Sci20: 198205, 1998.
122.
Iwami-MorimotoY, YamaguchiK, TanneK. Influence of dietary n-3 polyunsaturated fatty acid on experimental tooth movement in rats. Angle Orthod69: 365371, 1999.
123.
SchlemmerCK, CoetzerH, ClaassenN, KrugerMC. Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat. Prostaglandins Leukot Essent Fatty Acids61: 381390, 1999.
124.
DasUN. Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases. Prostaglandins Leukot Essent Fatty Acids44: 201210, 1991.
125.
ArendWP, DayerJM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum33: 305315, 1990.
126.
FukudaK, DanH, SaitohM, TakayamaM, TanakaS. Superoxide dismutase inhibits interleukin-1-induced degradation of human cartilage. Agents Actions42: 7173, 1994.
127.
FormigliL, OrlandiniSZ, TonelliP, GiannelliM, MartiniM, BrandiML, BergaminiM, OrlandiniGE. Osteolytic processes in human radicular cysts: Morphological and biochemical results. J Oral Pathol Med24: 216220, 1995.
128.
ShanbhagAS, MacaulayW, Stefanovic-RacicM, RubashHE. Nitric oxide release by macrophages in response to particulate wear debris. J Biomed Mater Res41: 497503, 1998.
129.
FranciniG, PetrioliR, MaioliE, GonnelliS, MarsiliS, AquinoA, BruniS. Hypercalcemia in breast cancer. Clin Exp Metastasis11: 359367, 1993.
FungHB, KirschenbaumHL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin Ther21: 11311157, 1999.
132.
BelchJJ, AnsellD, MadhokR, O'dowdA, SturrockRD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double blind placebo controlled study. Ann Rheum Dis47: 96104, 1988.
133.
CathcartES, GonnermanWA. Fish oil fatty acids and experimental arthritis. Rheum Dis Clin North Am17: 235242, 1991.
134.
KremerJM. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. Rheum Dis Clin North Am17: 391402, 1991.
135.
MagaroM, AltomonteL, ZoliA, MironeL, De SoleP, Di MarioG, LippaS, OradeiA. Influence of diet with different lipid composition on neutrophil chemiluminescence and disease activity in patients with rheumatoid arthritis. Ann Rheum Dis47: 793796, 1988.
136.
ClelandLG, FrenchJK, BettsWH, MurphyGA, ElliottMJ. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol15: 14711475, 1988.
137.
van der TempelH, TullekenJE, LimburgPC, MuskietFA, van RijswijkMH. Effects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis49: 7680, 1990.
138.
SkoldstamL, BorjessonO, KjallmanA, SeivingB, AkessonB. Effect of six months of fish oil supplementation in stable rheumatoid arthritis: A double-blind, controlled study. Scand J Rheumatol21: 178185, 1992.
139.
NielsenGL, FaarvangKL, ThomsenBS, TeglbjaergKL, JensenLT, HansenTM, LervangHH, SchmidtEB, DyerbergJ, ErnstE. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A randomized, double blind trial. Eur J Clin Invest22: 687691, 1992.
140.
SperlingRI, WeinblattM, RobinJL, RavaleseJIII, HooverRL, HouseF, CoblynJS, FraserPA, SpurBW, RobinsonDR. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum30: 988997, 1987.
141.
ShapiroJA, KoepsellTD, VoigtLF, DugowsonCE, KestinM, NelsonJL. Diet and rheumatoid arthritis in women: A possible protective effect of fish consumption. Epidemiology7: 256263, 1996.
142.
EndresS, GhorbaniR, KelleyVE, GeorgilisK, LonnemannG, van d MeerJW, CannonJG, RogersTS, KlempnerMS, WeberPC. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med320: 265271, 1989.
143.
KremerJM, LawrenceDA, JubizW, DiGiacomoR, RynesR, BartholomewLE, ShermanM. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: Clinical and immunologic effects. Arthritis Rheum33: 810820, 1990.
144.
CaugheyGE, MantziorisE, GibsonRA, ClelandLG, JamesMJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr63: 116122, 1996.
145.
KremerJM. Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Lipids31: S243S247, 1996.
146.
AlexanderJW. Immunonutrition: The role of omega-3 fatty acids. Nutrition14: 627633, 1998.
147.
Di BattistaJA, DoreS, MorinN, HeY, PelletierJP, MartelPJ. Prostaglandin E2 stimulates insulin-like growth factor binding protein-4 expression and synthesis in cultured human articular chondrocytes: Possible mediation by Ca++-calmodulin regulated processes. J Cell Biochem65: 408419, 1997.
148.
HishinumaT, NakamuraH, SawaiT, UzukiM, ItabashY, MizugakiM. Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. Prostaglandins Other Lipid Mediat58: 179186, 1999.
149.
SubbaramaiahK, ZakimD, WekslerBB, DannenbergAJ. Inhibition of cyclooxygenase: A novel approach to cancer prevention. Proc Soc Exp Biol Med216: 201210, 1997.
150.
KrishnanK, RuffinMT, BrennerDE. Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. J Cell Biochem28–29: 148158, 1997.
151.
GeusensP, WoutersC, NijsJ, JiangY, DequekerJ. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis: A 12-month, double-blind, controlled study. Arthritis Rheum37: 824829, 1994.
152.
RoseDP. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med216: 224233, 1997.
Yip-SchneiderMT, BarnardDS, BillingsSD, ChengL, HeilmanDK, LinA, MarshallSJ, CrowellPL, MarshallMS, SweeneyCJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis21: 139146, 2000.
155.
MarksF, FurstenbergerG, Muller-DeckerK. Arachidonic acid metabolism as a reporter of skin irritancy and target of cancer chemoprevention. Toxicol Lett96–97: 111118, 1998.
156.
AltmanGB, LeeCA. Strontium-89 for treatment of painful bone metastasis from prostate cancer. Oncol Nurs Forum23: 523527, 1996.
157.
BoyceBF, YonedaT, GuiseTA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer6: 333347, 1999.
158.
OrrFW, KostenuikP, Sanchez-SweatmanOH, SinghG. Mechanisms involved in the metastasis of cancer to bone. Breast Cancer Res Treat25: 151163, 1993.
159.
MeltonLJII. Epidemiology of fractures. In: RiggsBL, MeltonLJIII, Eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven Press, pp 133154, 1988.
160.
FujitaT. Osteoporosis in Japan: Factors contributing to the low incidence of hip fracture. Adv Nutr Res9: 8999, 1994.
161.
AdlercreutzH, MazurW. Phyto-oestrogens and Western diseases. Ann Med29: 95120, 1997.
162.
AndersonJJ, AnthonyMS, ClineJM, WashburnSA, GarnerSC. Health potential of soy isoflavones for menopausal women. Public Health Nutr2: 489504, 1999.
163.
BulliyyaG, ReddyPC, ReddyKN, ReddannaP. Fatty acid profile and the atherogenic risk in fish consuming and non-fish consuming people. Indian J Med Sci48: 256260, 1994.
164.
BrandiML. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcif Tissue Int61: S5S8, 1997.
165.
BlairHC, JordanSE, PetersonTG, BarnesS. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem61: 629637, 1996.
166.
YamaguchiM, GaoYH. Anabolic effect of genistein on bone metabolism in the femoral-metaphyseal tissues of elderly rats is inhibited by the anti-estrogen tamoxifen. Res Exp Med197: 101107, 1997.
167.
TodaS, ShiratakiY. Inhibitory effects of isoflavones on lipid peroxidation by reactive oxygen species. Phytother Res13: 163165, 1999.
168.
AroraA, ValcicS, CornejoS, NairMG, TimmermannBN, LieblerDC. Reactions of genistein with alkylperoxyl radicals. Chem Res Toxicol13: 638645, 2000.
169.
GaoYH, YamaguchiM. Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol58: 767772, 1999.
170.
BlancoA, HabibA, Levy-ToledanoS, MacloufJ. Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem J312: 419423, 1995.
171.
CorbettJA, KwonG, MarinoMH, RodiCP, SullivanPM, TurkJ, McDanielML. Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets. Am J Physiol270: C1581C1587, 1996.
172.
AstrucME, LahouaZ. Potentiation by cholesterol and vitamin D3 oxygenated derivatives of arachidonic acid release and prostaglandin E2 synthesis induced by the epidermal growth factor in NRK 49F cells: The role of protein kinase C. Cell Signal6: 763775, 1994.
173.
RuettenH, ThiemermannC. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: A possible role for protein tyrosine kinase. Br J Pharmacol122: 5970, 1997.
174.
SakamotoW, FujieK, NishihiraJ, HandaH, UedaN, YamamotoS. Effect of vitamin E on expression of cyclooxygenase-2 in lipopolysaccharide-stimulated rat macrophages. Biochim Biophys Acta1304: 139144, 1996.
175.
ParfenovaH, BalabanovaL, LefflerCW. Post-translational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am J Physiol274: C72C81, 1998.
176.
Kris-EthertonPM, TaylorDS, Yu-PothS, HuthP, MoriartyK, FishellV, HargroveRL, ZhaoG, EthertonTD. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr71: 179S188S, 2000.
177.
SimopoulosAP, LeafA, SalemNJr.. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab43: 127130, 1999.
